▶ 調査レポート

神経調節(ニューロモデュレーション)の世界市場:技術別(内部神経調節、外部神経調節(非侵襲性))、用途別(脊髄刺激(SCS)、脳深部刺激(DBS)、仙骨神経刺激、迷走神経刺激、胃電気刺激、経皮的電気神経刺激、反復経頭蓋磁気刺激、呼吸領域電気刺激)、地域別分析

• 英文タイトル:Global Neuromodulation Market - Segmented by Technology, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。神経調節(ニューロモデュレーション)の世界市場:技術別(内部神経調節、外部神経調節(非侵襲性))、用途別(脊髄刺激(SCS)、脳深部刺激(DBS)、仙骨神経刺激、迷走神経刺激、胃電気刺激、経皮的電気神経刺激、反復経頭蓋磁気刺激、呼吸領域電気刺激)、地域別分析 / Global Neuromodulation Market - Segmented by Technology, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08390資料のイメージです。• レポートコード:B-MOR-08390
• 出版社/出版日:Mordor Intelligence / 2018年5月23日
• レポート形態:英文、PDF、110ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Healthcare
• 販売価格(消費税別)
  Single User(1名様用)¥629,000 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥666,000 (USD4,500)▷ お問い合わせ
  Corporate User¥1,295,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、神経調節(ニューロモデュレーション)の世界市場について調べ、神経調節(ニューロモデュレーション)の世界規模、市場動向、市場環境、技術別(内部神経調節、外部神経調節(非侵襲性))分析、用途別(脊髄刺激(SCS)、脳深部刺激(DBS)、仙骨神経刺激、迷走神経刺激、胃電気刺激、経皮的電気神経刺激、反復経頭蓋磁気刺激、呼吸領域電気刺激)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・神経調節(ニューロモデュレーション)の世界市場インサイト
・神経調節(ニューロモデュレーション)の世界市場環境
・神経調節(ニューロモデュレーション)の世界市場動向
・神経調節(ニューロモデュレーション)の世界市場規模
・神経調節(ニューロモデュレーション)の世界市場規模:技術別(内部神経調節、外部神経調節(非侵襲性))
・神経調節(ニューロモデュレーション)の世界市場規模:用途別(脊髄刺激(SCS)、脳深部刺激(DBS)、仙骨神経刺激、迷走神経刺激、胃電気刺激、経皮的電気神経刺激、反復経頭蓋磁気刺激、呼吸領域電気刺激)
・神経調節(ニューロモデュレーション)の世界市場:地域別市場規模・分析
・神経調節(ニューロモデュレーション)の北米市場規模・予測
・神経調節(ニューロモデュレーション)のアメリカ市場規模・予測
・神経調節(ニューロモデュレーション)のヨーロッパ市場規模・予測
・神経調節(ニューロモデュレーション)のアジア市場規模・予測
・神経調節(ニューロモデュレーション)のインド市場規模・予測
・神経調節(ニューロモデュレーション)の韓国市場規模・予測
・関連企業情報・競争状況

The global neuromodulation market is expected to register a CAGR of about 14%, over the forecast period, 2018-2023. Neuromodulators are a subset of neurotransmitter. Unlike neurotransmitters, the release of neuromodulators occurs in a diffuse manner. This means that an entire neural tissue may be subject to the neuromodulator’s action due to exposure. This, in turn, can tune the neural circuitry of an entire brain region; not just that of an individual neuron.

Increase in the Aging Population to Fuel Market Growth

Neurological diseases are frequent in older adults, affecting around 55% of people age 55 and older. They are associated with a high risk for adverse health outcomes, including mortality, disability, institutionalization, and hospitalization. Degenerative diseases, like dementia and Parkinson’s disease, as well as strokes and headaches are frequently encountered neurological diseases in elderly patients. Neuromodulation is an intracranial, electrical neuromodulation therapy that has FDA approval for the treatment of the neurological most of the diseases, like bladder control, headache, tremors, chronic pain, stroke, minimally conscious state, and spinal cord injury, which are most commonly found in the elderly population. The proven efficacy and improving acceptance of this technology will lead to the surge in the market size during the forecast period. Other factors that will affect the growth of the market positively include rising prevalence of neurological disorders to spur market growth, strong product pipeline to propel the market, expanded target applications and new indications are expected to stimulate the growth of neuromodulation devices and investments and funds.

Inconsistent Reimbursement Policies Due to Lack of Practice Guide Lines

The lack of practice guidelines is a barrier to consistent application of the technology in practice, coverage, and reimbursement decisions. Without such guidelines, clinical decisions may be based on the opinions of independent practitioners who may or may not have experience with a technology and health plans setting coverage policy. Inconsistent reimbursement decisions may limit patient access to treatment and business development. This will also translate into slowdown of the growth of the neuromodulation market. Other factors that will act as restraints for the market include, lack of trained professionals likely to hamper market growth.

North America to Maintain Dominance

North America is the most attractive market in the neuromodulation industry and is estimated to be the first preference for new entrants due to the increasing faith in the technology and end-use in the region. Asia-Pacific is the fastest growing market; hence the established players are focusing on the region.

Key Developments in the Market:

• August 2017 – FDA Clears Xavant Technology’s Stimpod NMS460 Non-Invasive NeuromodulationDevice for Treatment of Chronic Intractable Pain

Major Players: BIOCONTROL MEDICAL, BOSTON SCIENTIFIC CORPORATION, CYBERONICS, INC., MEDTRONIC, INC., NEURONETICS, INC., NEUROPACE, INC., NEUROSIGMA, INC., NEVRO CORPORATION, ST. JUDE MEDICAL, INC. AND SYNAPSE BIOMEDICAL, INC., amongst others.

Reasons to Purchase the Report

• Current and future neuromodulation market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Prevalence of Neurological Disorders to Spur Market Growth
6.1.2 Increase in the Aging Population to Fuel Market Growth
6.1.3 Strong Product Pipeline to Propel the Market
6.1.4 Expanded Target Applications and New Indications are Expected to Stimulate the Growth of Neuromodulation Devices
6.1.5 Investments and Funds
6.2 Market Restraints
6.2.1 Inconsistent Reimbursement Policies Due to Lack of Practice Guide Lines
6.2.2 Lack of Trained Professionals Likely to Hamper Market Growth
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Technology
7.1.1 Internal Neuromodulation
7.1.1.1 Spinal Cord Stimulation (SCS)
7.1.1.2 Deep Brain Stimulation (DBS)
7.1.1.3 Vagus Nerve Stimulation (VNS)
7.1.1.4 Sacral Nerve Stimulation (SNS)
7.1.1.5 Gastric Electrical Stimulation (GES)
7.1.2 External Neuromodulation (Non-Invasive)
7.1.2.1 Transcutaneous Electrical Nerve Stimulation (Tens)
7.1.2.2 Transcranial Magnetic Stimulation (TMS)
7.1.2.3 Respiratory Electrical Stimulation (RES)
7.2 By Application
7.2.1 Spinal Cord Stimulation (SCS) Market, By Application
7.2.2 Deep Brain Stimulation (DBS) Market, By Application
7.2.3 Sacral Nerve Stimulation Market, By Application
7.2.4 Vagus Nerve Stimulation Market, By Application
7.2.5 Gastric Electrical Stimulation Market, By Application
7.2.6 Transcutaneous Electrical Nerve Stimulation Market, By Application
7.2.7 Repetitive Transcranial Magnetic Stimulation Market, By Application
7.2.8 Respiratory Electrical Stimulation Market, By Application
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 India
7.3.3.2 Australia & New Zealand
7.3.3.3 South Korea
7.3.3.4 Rest of Asia-Pacific
7.3.4 Rest of World
7.3.4.1 Saudi Arabia
7.3.4.2 Brazil
7.3.4.3 Others
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Biocontrol Medical
9.2 Boston Scientific Corporation
9.3 Cyberonics, Inc.
9.4 Medtronic, Inc.
9.5 Neuronetics, Inc.
9.6 Neuropace, Inc.
9.7 Neurosigma, Inc.
9.8 Nevro Corporation
9.9 ST. Jude Medical, Inc.
9.10 Synapse Biomedical, Inc.
*List Not Exhaustive
10. Future of the Market